James A. Schoeneck

President and Chief Executive Officer
Depomed, Inc.

Mr. Schoeneck joined Depomed as president and chief executive officer in April 2011 and has served as a director of the company’s board since December 2007. Prior to his appointment as Depomed’s president and chief executive officer, he served as chief executive officer of BrainCells Inc., a private biopharmaceutical company in San Diego, CA, since 2005. Mr. Schoeneck's broad pharmaceutical experience includes three years as the president and chief executive officer of Prometheus Laboratories Inc., a specialty pharmaceutical company. At Prometheus, Mr. Schoeneck led the company to profitability and rapid revenue growth, increasing sales from $6 million to over $70 million. Under Mr. Schoeneck's leadership, Prometheus was recognized as the third fastest growing private company in America by Inc. magazine. Prior to Prometheus, Mr. Schoeneck spent three years at Centocor, Inc., where he led the development of Centocor's commercial capabilities, growing his team from three people to almost 500 in less than three years. His group launched Remicade®, which has become the world's fifth largest selling pharmaceutical product, with over $7 billion in sales in 2010. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility, including the launch of products that generated over $300 million in annual sales. Prior to joining BrainCells, he was chief executive officer of ActivX BioSciences, a development stage biotechnology company. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University.